Effects of hyperbaric oxygen combined with salmeterol xinafoate and fluticasone propionate powder for inhalation on pulmonary function and serum levels of COX-2 and MMP-9 in patients with stable COPD
10.3760/cma.j.cn311847-20201118-00427
- VernacularTitle:高压氧联合沙美特罗替卡松粉吸入剂对慢性阻塞性肺病稳定期患者肺功能及血清COX-2、MMP-9水平的影响
- Author:
Dezhen ZHANG
1
;
Ce SHI
1
;
Anmeng WEI
1
Author Information
1. 476000 河南省商丘，商丘市第一人民医院呼吸与危重症医学科
- Publication Type:Journal Article
- Keywords:
Hyperbaric oxygen;
Salmeterol xinafoate and fluticasone propionate powder for inhalation;
Chronic obstructive pulmonary disease;
Pulmonary function
- From:
Chinese journal of nautical medicine and hyperbaric medicine
2021;28(3):326-329
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effects of hyperbaric oxygen (HBO) combined with salmeterol xinafoate and fluticasone propionate powder for inhalation (trade name: Seretide) on pulmonary function and serum levels of cyclooxygenase-2 (COX-2) and matrix metalloproteinase-9 (MMP-9) in patients with stable chronic obstructive pulmonary disease (COPD).Methods:A total of 96 patients with stable COPD treated in the First People’s Hospital of Shangqiu from February 2019 to February 2020 were selected and randomly divided into control group ( n=48) and observation group ( n=48) by the random number table method. The control group was treated with salmeterol xinafoate and fluticasone propionate powder for inhalation (50 μg salmeterol and 250 μg fluticasone propionate), and the observation group was treated with HBO on the basis of the treatment of the control group. The clinical efficacy, symptom disappearance time, pulmonary function measured by forced respiratory volume in one second (FEV1) before and after treatment, the ratio of FEV to forced vital capacity (FEV/FVC) and the ratio of FEV1 to predicted value (FEV1/Pred), and the serum levels COX-2 and MMP-9 were compared between the two groups. Results:The total effective rate of the observation group (97.92%) was significantly higher than that of the control group (83.33%), with a statistically significant difference ( P<0.05). After treatment, the recovery time of normal body temperature, the disappearance time of cough and lung rale, and the recovery time of leukocytes in the observation group were significantly shorter than those in the control group, and the differences were statistically significant ( P<0.05 or P<0.01). After treatment, the levels of FEV1, the ratios of FEV/FVC and FEV1/Pred in the observation group were significantly higher than those in the control group, while the serum levels of COX-2 and MMP-9 in the observation group were significantly lower than those in the control group, and the differences were statistically significant ( P<0.01). Conclusion:HBO combined with salmeterol xinafoate and fluticasone propionate powder for inhalation has significant clinical effects on patients with stable COPD by improving their pulmonary function and reducing their serum levels of COX-2 and MMP-9.
